Welcome to our dedicated page for CRVN news (Ticker: CRVN), a resource for investors and traders seeking the latest updates and insights on CRVN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRVN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRVN's position in the market.
Cerevance announced positive Phase 1 trial results for CVN293, a novel KCNK13 inhibitor targeting neuroinflammation, at the American Academy of Neurology 2025 Annual Meeting. The randomized, double-blind, placebo-controlled study involved 72 healthy adults, evaluating single doses up to 1,000 mg and multiple doses up to 750 mg over 14 days.
Key findings showed that CVN293 was well-tolerated with:
- 100% participant completion rate
- No severe or dose-limiting adverse events
- Only mild treatment-related effects
- High levels of central nervous system exposure
- Generally dose-proportional plasma exposure
The company also presented data on their NETSseq platform and solengepras, a non-dopaminergic therapy in development for Parkinson's disease, including results from the Phase 2 ASCEND study in early, untreated Parkinson's patients.
Cerevance has announced topline results from its Phase 2 ASCEND trial of solengepras, an investigational monotherapy for early-stage Parkinson's disease. The oral, non-dopaminergic therapy showed potential benefits in functional and non-motor symptoms versus placebo.
Key findings include:
- Small, non-statistically significant improvement in motor symptoms (MDS-UPDRS Parts II+III)
- Trends in improvement observed in patient-reported measures including MDS-UPDRS Part I (-1.38, p=0.12) and Part II (-0.4, p=0.62)
- 100% patient completion rate with no serious adverse events related to the treatment
- Fewer adverse events related to non-motor symptoms in the treatment arm compared to placebo
The company's pivotal Phase 3 ARISE trial evaluating solengepras as adjunctive therapy in Parkinson's disease is ongoing, with topline data expected in first half of 2026.
Cerevance has announced upcoming presentations of clinical trial results at two major medical conferences in April 2025: the AD/PD™ 2025 in Vienna and the AAN Annual Meeting in San Diego. The key highlight will be the topline results from the Phase 2 ASCEND trial of solengepras (CVN424) as a monotherapy treatment for early-stage Parkinson's disease.
The company will also present first-time data from a Phase 1 trial of CVN293, a novel KCNK13 inhibitor targeting neuroinflammation in CNS diseases. Additional presentations will showcase their proprietary NETSseq platform's potential in identifying novel therapeutic targets for neurodegenerative diseases.
